Author

Riccardo Valdez

University of Michigan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:metabolism & bioenergetics· 1 Assay:proteomics· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Aubree L. GordoniD· 5 shared David D. HoiD· 5 shared Ian A. MellisiD· 5 shared Qian WangiD· 5 shared Madeline Wu· 4 shared Yicheng Guo· 4 shared Anthony D. BoweniD· 3 shared Carmen GherasimiD· 3 shared

Activity by Year

2024-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

Aubree L. GordonORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Do Existing COVID-19 Vaccines Need to Be Updated in 2025?

Ian A. Mellis, Madeline Wu, Qian Wang, Anthony D. Bowen, Carmen Gherasim, Riccardo Valdez, Jayesh Shah, Lawrence J. Purpura, Michael T. Yin, Aubree L. Gordon, Yicheng Guo, David D. Ho

This study assesses whether 2025 COVID-19 vaccines need updating by testing neutralizing antibody titers against emerging variants in individuals vaccinated with KP.2-based mRNA vaccines.

bioRxiv · May 2, 2025 · PreprintMicrobiology

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC

Qian Wang, Yicheng Guo, Ian A. Mellis, Madeline Wu, Hiroshi Mohri, Carmen Gherasim, Riccardo Valdez, Lawrence J. Purpura, Michael T. Yin, Aubree L. Gordon, David D. Ho

This study evaluates the antibody evasion of SARS-CoV-2 subvariants KP.3.1.1 and XEC compared to their parental variants, finding increased resistance to neutralization by sera and antibodies targeting the spike protein.

Cell Reports · Apr 1, 2025Peer-reviewedMicrobiology

KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2

Qian Wang, Ian A. Mellis, Madeline Wu, Anthony D. Bowen, Carmen Gherasim, Riccardo Valdez, Jayesh Shah, Lawrence J. Purpura, Michael T. Yin, Aubree L. Gordon, Yicheng Guo, David D. Ho

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

The Lancet Infectious Diseases · Feb 4, 2025Peer-reviewedMicrobiology

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages

Qian Wang, Ian A. Mellis, Jerren Ho, Anthony D. Bowen, Theresa Kowalski-Dobson, Riccardo Valdez, Phinikoula S. Katsamba, Madeline Wu, Caitlin Lee, Lawrence S. Shapiro, Aubree Gordon, Yicheng Guo, David D. Ho, Lihong Liu

This study examines how recurrent spike mutations in SARS-CoV-2 JN.1 sublineages affect immune evasion, ACE2 affinity, and infectivity, identifying growth advantages in specific sublineages.

Emerging Microbes & Infections · Sep 11, 2024Peer-reviewedMicrobiology

SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1

Qian Wang, Yicheng Guo, Logan T. Schwanz, Ian A. Mellis, Yiwei Sun, Yiming Qu, Guillaume Urtecho, Riccardo Valdez, Emily Stoneman, Aubree Gordon, Harris H. Wang, David D. Ho, Lihong Liu

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

bioRxiv · Mar 10, 2024Microbiology